NYSE:MYM MyMD Pharmaceuticals (MYM) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free MYM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume18,855 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get MyMD Pharmaceuticals alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About MyMD Pharmaceuticals Stock (NYSE:MYM)BlackRock MuniYield Michigan Quality Fund II, Inc. (the Fund) is a non-diversified, closed-end management investment company. The Fund's investment objective is to provide shareholders with as high a level of current income exempt from federal and Michigan income taxes as is consistent with its investment policies and prudent investment management. The Fund seeks to achieve its investment objective by investing at least 80% of its assets in municipal obligations exempt from federal income taxes (except that the interest may be subject to the federal alternative minimum tax) and Michigan income taxes. Generally, the Fund invests primarily in long-term municipal obligations that are investment grade quality at the time of investment. The Fund invests in health, education, county/city/special district/school district, state, utilities, transportation, housing and corporate sectors. BlackRock Advisors, LLC is the investment advisor of the Fund.Read More Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. MYM Stock News HeadlinesApril 20, 2024 | msn.comAsia FX weakens; yen, dollar rise on fears of Iran-Israel escalationApril 13, 2024 | uk.investing.comJPMorgan’s India equity preview favors domestic cyclical playsApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 11, 2024 | msn.comOil prices steady amid Middle East tensions, US inventory buildApril 8, 2024 | finanznachrichten.deDelveInsight Business Research, LLP: Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsightApril 8, 2024 | msn.comSwiss National Bank's Jordan against issuing retail cenbank digital currencyApril 8, 2024 | uk.investing.comEaster food spending lifts UK retail sales by most since AugustApril 8, 2024 | finance.yahoo.comGiant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsightApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.March 27, 2024 | uk.investing.comFashion retailer H&M's Q1 operating profit rises more than expectedMarch 27, 2024 | uk.investing.comMost rescue efforts at Russian gold mine have been suspended due to risk of another collapse -TASSMarch 18, 2024 | finance.yahoo.comSarcopenia Market Expected to Grow with Advancements in Treatment and Diagnosis by 2032February 13, 2024 | finance.yahoo.comMyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq ListingDecember 28, 2023 | benzinga.comMyMD Pharmaceuticals Releases Positive Clinical Trial Results For Sarcopenia Treatment DrugDecember 6, 2023 | finance.yahoo.comMyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid ArthritisOctober 4, 2023 | finance.yahoo.comMyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023August 25, 2023 | benzinga.comMyMD Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively BuyingAugust 9, 2023 | bizjournals.comBaltimore's MIRA Pharmaceuticals raises $8.9 million from IPOJuly 31, 2023 | msn.comWhy Is MyMD Pharmaceuticals Stock Gaining Today?July 6, 2023 | msn.comWhy Caribou Biosciences Shares Are Trading Higher By Around 58%? Here Are Other Stocks Moving In Thursday's SessionMay 1, 2023 | msn.comUnusual Call Option Trade in MyMD Pharmaceuticals (MYMD) Worth $15.98KApril 12, 2023 | msn.comMyMD stock dips amid dosing updates on aging therapy MYMD-1March 8, 2023 | finance.yahoo.comMyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent TrollsMarch 2, 2023 | msn.comMyMD says DEA found that its cannabinoid Supera-CBD is not a controlled substanceMarch 2, 2023 | msn.comDEA Concludes MyMD's Supera-CBD Is Not A Controlled Substance Or Listed ChemicalFebruary 21, 2023 | msn.comMyMD Pharmaceuticals to raise $15M from current investorsJanuary 12, 2023 | markets.businessinsider.comGlenmark Pharmaceuticals launches Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose VialsSee More Headlines Receive MYM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MyMD Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNYSE SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNYSE:MYM CUSIPN/A CIKN/A WebN/A PhoneN/AFaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report MYM Stock Analysis - Frequently Asked Questions What other stocks do shareholders of MyMD Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other MyMD Pharmaceuticals investors own include Castleton Technology (CTP), Richland Resources Ltd (RLD.L) (RLD), Thor Energy (THR), (DARA) (DARA), Global Invacom Group (GINV), Legendary Investments (LEG), Clontarf Energy (CLON), iPass (IPAS) and MoSys (MOSY). This page (NYSE:MYM) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MyMD Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
